Pantoprazole Hikma Farmacêutica (Portugal)

Pantoprazole, the active ingredient in Pantoprazole Hikma Farmacêutica (Portugal), is a proton‑pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Pantoprazole Hikma Farmacêutica (Portugal) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazole Hikma Farmacêutica (Portugal) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is indicated for acid‑related disorders that involve excessive gastric acid secretion.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates mucosal healing and reduces recurrence. - Peptic ulcer disease: supports ulcer healing and helps prevent relapse. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid. - Helicobacter pylori eradication regimens: used as adjunct therapy to improve eradication rates.

Pantoprazole is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Acute interstitial nephritis - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Clostridioides difficile‑associated colitis - Hypomagnesemia - Osteoporosis‑related fractures - Liver enzyme abnormalities (hepatitis)

When prescribing Pantoprazole, clinicians should consider several safety aspects.

- Renal impairment: dose adjustment may be required in severe kidney disease. - Hepatic impairment: monitor liver function in patients with existing liver disease. - Long‑term use: assess risk of bone fractures and vitamin B12 deficiency. - Drug interactions: review concomitant medications for potential CYP‑mediated effects. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Methotrexate: reduced renal clearance, watch for toxicity. - Digoxin: possible increase in serum levels, check therapeutic range. - Clopidogrel: diminished antiplatelet effect, consider alternative therapy.